Financial News
Articles published by AstraZeneca
![](https://mms.businesswire.com/media/20240206590080/en/2022896/22/MCD_-_approved.jpg)
![](https://mms.businesswire.com/media/20240129083517/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20240122150188/en/2004732/5/Kenneth_Mendez_AAFA.jpg)
![](https://mms.businesswire.com/media/20240119724994/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231225813821/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231221289590/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231212478740/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231129660794/en/484259/5/Logo.jpg)
AstraZeneca advances scientific leadership in hematology at ASH 2023
November 29, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20231120504578/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231117656421/en/484259/5/Logo.jpg)
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
November 17, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20231109899785/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231108938138/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231103874324/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231024664223/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231023622586/en/1922499/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231023650458/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231023654115/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231022399320/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231021558683/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231021219386/en/484259/5/Logo.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20231016244119/en/484259/5/Logo.jpg)
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
October 16, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20231011003940/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20231011196376/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20230922179550/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20230912906025/en/1888273/5/AZ_CMYK_H_COL.jpg)
![](https://mms.businesswire.com/media/20230911052398/en/484259/5/Logo.jpg)
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
September 11, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20230911121282/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20230911597442/en/484259/5/Logo.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.